Michael Barbella, Managing Editor06.24.22
China's orthopedic market is forecast to lose 45 percent in total value this year due to volume-based procurement (VBP) programs.
The $3 billion market (2021 value) is likely to fall 45% to $1.7 billion ithis year from the impact of ongoing VBP programs, predicts GlobalData.
VBP programs in China integrate a larger purchasing volume with a lower price to suppress the inflated prices of high-value medical devices. High-value orthopedic implants is the major focus of VBP and has led to a steep price reduction, ranging between 55% and 84% for spinal, hip, and knee implants.
“China’s orthopedic devices market can be segmented into hip and knee replacement, spinal replacement, trauma fixation, arthroscopic devices, orthobiologics, and others," said Tina Deng, MSc, a principal medical devices analyst at GlobalData. "Approximately 76% of the revenue is from hip and knee replacement, spinal replacement, and trauma fixation, which have all been heavily impacted by VBP. Multi-national companies (MNCs) used to control over 60% of major markets, but the competitive landscapes have changed rapidly. Domestic companies with excellent cost control, diverse portfolio, and optimal pricing strategy have won more share in the markets that do not have high technical barriers.”
The domestic players’ share in trauma fixation devices has reached a high level. In the previous VBP program of the 12 provinces, the domestic devices were 935,600 sets, accounting for 96.7%, whereas the demand for imported products was 32,000 sets, accounting for only 3.3%. The major domestic players, including Dabo, Zhengtian, and Weigao, enjoyed a high proportion of the trauma fixation devices market in the region. These companies are very likely to control more shares this year at the country level.
“Orthopedic manufacturers need to keep investing in R&D to improve technology and develop new products, especially for devices that are not on the VBP list. Future direction includes novel absorbable materials in the trauma market, 3D-printed spinal implants, and orthopedic surgical robots in the spine and joint market,” Deng said.
The $3 billion market (2021 value) is likely to fall 45% to $1.7 billion ithis year from the impact of ongoing VBP programs, predicts GlobalData.
VBP programs in China integrate a larger purchasing volume with a lower price to suppress the inflated prices of high-value medical devices. High-value orthopedic implants is the major focus of VBP and has led to a steep price reduction, ranging between 55% and 84% for spinal, hip, and knee implants.
“China’s orthopedic devices market can be segmented into hip and knee replacement, spinal replacement, trauma fixation, arthroscopic devices, orthobiologics, and others," said Tina Deng, MSc, a principal medical devices analyst at GlobalData. "Approximately 76% of the revenue is from hip and knee replacement, spinal replacement, and trauma fixation, which have all been heavily impacted by VBP. Multi-national companies (MNCs) used to control over 60% of major markets, but the competitive landscapes have changed rapidly. Domestic companies with excellent cost control, diverse portfolio, and optimal pricing strategy have won more share in the markets that do not have high technical barriers.”
The domestic players’ share in trauma fixation devices has reached a high level. In the previous VBP program of the 12 provinces, the domestic devices were 935,600 sets, accounting for 96.7%, whereas the demand for imported products was 32,000 sets, accounting for only 3.3%. The major domestic players, including Dabo, Zhengtian, and Weigao, enjoyed a high proportion of the trauma fixation devices market in the region. These companies are very likely to control more shares this year at the country level.
“Orthopedic manufacturers need to keep investing in R&D to improve technology and develop new products, especially for devices that are not on the VBP list. Future direction includes novel absorbable materials in the trauma market, 3D-printed spinal implants, and orthopedic surgical robots in the spine and joint market,” Deng said.